3PO

Key Product Details

Product Description

3PO is originally reported to inhibit PFKFB3 (IC₅₀ = 25 μM). More recent reports failed to demonstrate activity in a PFKFB3 kinase assay. Reduces glycolytic flux and suppresses glucose uptake. Inhibits endothelial cell proliferation and causes G₂/M cell cycle arrest in vitro. Attenuates vessel sprouting and tumor growth in vivo. Amplifies the antiangiogenic effect of VEGFR blockade.

Product Specifications for 3PO

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for 3PO

The following data is based on the product molecular weight 210.23.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.76 mL	23.78 mL	47.57 mL
5 mM	0.95 mL	4.76 mL	9.51 mL
10 mM	0.48 mL	2.38 mL	4.76 mL
50 mM	0.10 mL	0.48 mL	0.95 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Schoors Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014 PMID: 24332967
• Boyd Structure-based design of potent and selective inhibitors of the metabolic kinase PFKFB3. J.Med.Chem. 2015 PMID: 25849762
• Clem Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol.Cancer Ther. 2008 PMID: 18202014

Product Documents for 3PO